文献速递胸部肿瘤

帕博利珠单抗联合化疗一线治疗转移性鳞状非小细胞肺癌:KEYNOTE-407最终分析

A Randomized, Placebo-Controlled Trial of Pembrolizumab Plus Chemotherapy in Patients With Metastatic Squamous NSCLC: Protocol-Specified Final Analysis of KEYNOTE-407.
PubMed 文献 · J Thorac Oncol · 2020-06-26

KEYNOTE-407研究方案预设最终分析显示,在转移性鳞状非小细胞肺癌患者中,帕博利珠单抗联合化疗较安慰剂联合化疗持续改善总生存(中位17.1个月 vs 11.6个月,HR 0.71)和无进展生存(中位8.0个月 vs 5.1个月,HR 0.57),且PFS-2支持其作为一线标准治疗。

要点

  • 帕博利珠单抗联合化疗较安慰剂联合化疗显著改善OS(HR 0.71)和PFS(HR 0.57)。
  • PFS-2在帕博利珠单抗联合化疗组更长(HR 0.59),支持一线使用。
  • 3-5级不良事件发生率两组分别为74.1%和69.6%。

核心结论

  • 帕博利珠单抗联合化疗在转移性鳞状NSCLC中持续显示OS和PFS获益,PFS-2结果支持其作为一线标准治疗。

研究设计与样本

  • 随机安慰剂对照试验KEYNOTE-407,纳入既往未治疗的转移性鳞状NSCLC患者,随机接受化疗联合帕博利珠单抗(n=278)或安慰剂(n=281)。
  • 主要终点为OS和PFS,PFS-2为探索性终点;中位随访14.3个月(范围0.1-31.3)。

主要发现

  • 帕博利珠单抗联合化疗组中位OS为17.1个月(95%CI 14.4-19.9),安慰剂联合化疗组为11.6个月(95%CI 10.1-13.7),HR 0.71(95%CI 0.58-0.88)。
  • 帕博利珠单抗联合化疗组中位PFS为8.0个月(95%CI 6.3-8.4),安慰剂联合化疗组为5.1个月(95%CI 4.3-6.0),HR 0.57(95%CI 0.47-0.69)。
  • PFS-2在帕博利珠单抗联合化疗组更长,HR 0.59(95%CI 0.49-0.72)。
  • 3-5级不良事件发生率在帕博利珠单抗联合化疗组为74.1%,安慰剂联合化疗组为69.6%。

临床怎么用

  • 对于既往未治疗的转移性鳞状NSCLC患者,帕博利珠单抗联合卡铂和紫杉醇/白蛋白紫杉醇可作为一线标准治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: In the randomized KEYNOTE-407 study (ClinicalTrials.gov, NCT02775435), pembrolizumab plus carboplatin and paclitaxel/nab-paclitaxel (chemotherapy) significantly improved overall survival (OS) and progression-free survival (PFS) compared with placebo plus chemotherapy in patients with previously untreated metastatic squamous NSCLC. We report updated efficacy outcomes from the protocol-specified final analysis and, for the first time, progression on next line of treatment. METHODS: Eligible patients were randomized to chemotherapy plus either pembrolizumab (n = 278) or placebo (n = 281). After positive results from the second interim analysis, patients still receiving placebo could cross over to pembrolizumab monotherapy at the time of confirmed progressive disease. The primary end points were OS and PFS. PFS-2 (time from randomization to progression on next-line treatment/death, whichever occurred first) was an exploratory end point. RESULTS: After median (range) follow-up of 14.3 (0.1-31.3) months, pembrolizumab plus chemotherapy continued to exhibit a clinically meaningful improvement over placebo plus chemotherapy in OS (median, 17.1 mo [95% confidence interval (CI): 14.4‒19.9] versus 11.6 mo [95% CI: 10.1‒13.7]; hazard ratio [HR], 0.71 [95% CI: 0.58‒0.88]) and PFS (median, 8.0 mo [95% CI: 6.3‒8.4] versus 5.1 mo [95% CI: 4.3‒6.0]; HR, 0.57 [95% CI: 0.47‒0.69]). PFS-2 was longer for patients randomized to first-line pembrolizumab plus chemotherapy (HR, 0.59 [95% CI: 0.49‒0.72]). Grade 3 to 5 adverse events occurred in 74.1% and 69.6% of patients receiving pembrolizumab plus chemotherapy and placebo plus chemotherapy, respectively. CONCLUSIONS: Pembrolizumab plus chemotherapy continued to exhibit substantially improved OS and PFS in patients with metastatic squamous NSCLC. The PFS-2 outcomes support pembrolizumab plus chemotherapy as a standard first-line treatment in patients with metastatic squamous NSCLC.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Paz-Ares L, Vicente D, Tafreshi A, et al. A Randomized, Placebo-Controlled Trial of Pembrolizumab Plus Chemotherapy in Patients With Metastatic Squamous NSCLC: Protocol-Specified Final Analysis of KEYNOTE-407. J Thorac Oncol. 2020. PMID: 32599071. doi:10.1016/j.jtho.2020.06.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。